LGD-6972 _Glucagon Receptor Antagonist - MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemELGD-6972Cat. No.: HY-12525CAS No.: 1207989-09-0分式: CHNOS分量: 702.9作靶点: Glucagon Receptor作通路: GPCR/G Protein储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性数据体外实验 DMSO : 31 mg/mL (44.10 mM)* means soluble,

2、 but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制备储备液1 mM 1.4227 mL 7.1134 mL 14.2268 mL5 mM 0.2845 mL 1.4227 mL 2.8454 mL10 mM 0.1423 mL 0.7113 mL 1.4227 mL请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液，并请注意储备液的保存式和期限。BIOLOGICAL ACTIVITY物活性 LGD-6972种胰糖素受体拮抗剂。体内研究LGD-6972 has linear plasma pharmacoki

3、netics consistent with once daily dosing that is comparable inhealthy and T2DM subjects. Dose-dependent decreases in fasting plasma glucose are observed in all groupswith a maximum of 3.15 mM (56.8 mg/dL) on day 14 in T2DM subjects. LGD-6972 also reduces plasmaglucose in the postprandial state. Dose

4、-dependent increases in fasting plasma glucagon are observed, but1/2 Master of Small Molecules 您边的抑制剂师www.MedChemEglucagon levels decrease and insulin levels increase after an oral glucose load in T2DM subjects. LGD-6972is well tolerated at the doses tested without dose-related or clinically meaning

5、ful changes in clinicallaboratory parameters. No subject experiences hypoglycaemia 1.REFERENCES1. Vajda EG, et al. Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD-6972in healthy subjects and subjects with type 2 diabetes mellitus. Diabetes Obes Metab. 2017 Jan;19(1):24-32.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400-820-3792; 0